180 recruiting. 180 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 180 | Recruiting 180 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Foquest in Adults 65 Years and Older With ADHD Methylphenidate hydrochloride extended-release capsules - Attention Deficit Hyperactivity Disorder | Phase 4 | Recruiting | Dar Clinical Research Inc. | 36 | 2026-10-06 | 2026-10-07 |
| Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic Buprenorphine - Opioid Use Disorder | Phase 4 | Recruiting | Yale University | 60 | 2026-09-23 | 2026-10-09 |
| Caplyta Versus Placebo for Adults With Social Anxiety Disorder Lumateperone 42 mg, Placebo - Social Anxiety Disorder (SAD) | Phase 4 | Recruiting | Jason Careri | 40 | 2026-09-10 | 2026-09-15 |
| The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar Depression Lumateperone 42 mg - Bipolar Depression Depressed Phase, Obesity & Overweight | Phase 4 | Recruiting | Massachusetts General Hospital | 25 | 2026-09-09 | 2026-09-11 |
| A Bundled Intervention to End Opioid Overdoses Bundled intervention (Experimental), control group, Buprenorphine (Experimental) - Opioid Use Disorder, Opioid Overdose | Phase 4 | Recruiting | University of Alabama at Birmingham | 160 | 2026-09-07 | 2026-10-02 |
| Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients Lemborexant, Placebo - Sleep Disturbance, Delirium | Phase 4 | Recruiting | Mahidol University | 100 | 2026-09-01 | 2026-10-08 |
| Buspirone for Anxiety in Autistic Youth buspirone, Placebo - Anxiety, Autism Spectrum Disorder | Phase 4 | Recruiting | Massachusetts General Hospital | 20 | 2026-09-01 | 2026-09-17 |
| Comparing the Efficacy of Propofol and Dexmedetomidine in Prevention of Emergence Agitation After Sevoflurane Anesthesia in Children propofol 1mg/kg, Dexmedetomidine - Emergence Delirium, Anesthesia | Phase 4 | Recruiting | Pakistan Institute of Medical Sciences | 114 | 2026-08-28 | 2026-09-02 |
| Varenicline for Smoking Reduction in Veterans Not Ready To Quit Motivation-Phase Varenicline, Motivation-Phase Nicotine Mini-Lozenge, Cessation-Phase Combination Nicotine Replacement Therapy (NRT) - Veterans, Tobacco Use Disorder | Phase 4 | Recruiting | VA Office of Research and Development | 400 | 2026-08-17 | 2026-08-31 |
| Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction Tadalafil; Current on-demand PDE5 inhibitor, Tadalafil 5 mg - Erectile Dysfunction, Tadalafil | Phase 4 | Recruiting | Al-Azhar University | 260 | 2026-08-13 | 2026-09-01 |
| Biomarker-Guided Antidepressant Selection TMS, Ketamine - Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD) | Phase 4 | Recruiting | Weill Medical College of Cornell University | 27 | 2026-08-10 | 2026-09-23 |
| Neuromodulation of Mood Switch Circuitry in Bipolar Disorder MagVenture MagPro TMS system, Sham Stimulation - Bipolar Disorder (BD), Bipolar 1 Depression | Phase 4 | Recruiting | Weill Medical College of Cornell University | 62 | 2026-08-03 | 2026-09-23 |
| Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers Lecanemab - Alzheimer Disease | Phase 4 | Recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 100 | 2026-07-10 | 2026-07-07 |
| Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study) Varenicline, Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham - Nicotine Dependence, Transcranial Magnetic Stimulation | Phase 4 | Recruiting | Massachusetts General Hospital | 30 | 2026-07-02 | 2026-09-15 |
| Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis Acoramidis (AG10) oral tablet - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis | Phase 4 | Recruiting | Eidos Therapeutics, a BridgeBio company | 150 | 2026-07-01 | 2026-07-29 |
| Propofol-Only Versus Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Dexmedetomidine (IV) 0.5 mcg/kg, Propofol (IV) 2-4 mg/kg, Dexmedetomidine (IV) 1 mcg/kg - MRI Sedation, Pediatric Sedation | Phase 4 | Recruiting | Boston Children's Hospital | 105 | 2026-06-30 | 2026-09-21 |
| Diphenhydramine as an Adjunct to Moderate Sedation for Procedural First Trimester Abortions Diphenhydramine, Placebo - Pain, Abortion | Phase 4 | Recruiting | University of Rochester | 98 | 2026-06-29 | 2026-08-21 |
| Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities Deutetrabenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Recruiting | University Hospitals Cleveland Medical Center | 25 | 2026-06-22 | 2026-07-06 |
| L-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction L-Citrulline, Tadalafil, L-Citrulline Placebo - Erectile Dysfunction | Phase 4 | Recruiting | Beni-Suef University | 133 | 2026-06-08 | 2026-06-12 |
| Comprehensive Toileting Program Glycerin Suppository, Behavioral strategies - Encopresis, ASD | Phase 4 | Recruiting | Emory University | 150 | 2026-06-01 | 2026-06-18 |
Showing 20 of 180. Sign in to see all of them.
Depression (18) · Psychotic Disorders (17) · Depressive Disorder, Major (16) · Anxiety Disorders (15) · Schizophrenia (15) · Attention Deficit Disorder with Hyperactivity (14) · Opioid-Related Disorders (14) · Emergence Delirium (12) · Sleep Initiation and Maintenance Disorders (12) · Bipolar Disorder (11) · Alzheimer Disease (10) · Tobacco Use Disorder (9) · Cognitive Dysfunction (8) · Stress Disorders, Post-Traumatic (8) · Depressive Disorder, Treatment-Resistant (5)
Nervous System Diseases (62) · Pathological Conditions, Signs and Symptoms (47) · Signs and Symptoms (38) · Behavior (36) · Neurocognitive Disorders (36) · Neurologic Manifestations (34) · Chemically-Induced Disorders (32) · Mood Disorders (31) · Substance-Related Disorders (27) · Central Nervous System Diseases (26) · Brain Diseases (24) · Behavioral Symptoms (23) · Depressive Disorder (23) · Neurobehavioral Manifestations (23)
Ketamine (9) · Dexmedetomidine (7) · Methylphenidate (7) · Clozapine (6) · Propofol (6) · Buprenorphine (5) · Cognitive Behavioral Therapy (5) · Therapeutics (5) · Varenicline (5) · Escitalopram (4) · Esketamine (4) · Risperidone (4) · Sertraline (4) · lemborexant (4) · Buprenorphine, Naloxone Drug Combination (3)
Centre for Addiction and Mental Health (7) · Massachusetts General Hospital (7) · VA Office of Research and Development (7) · Mayo Clinic (5) · Nova Scotia Health Authority (4) · NYU Langone Health (3) · Yale University (3) · Aalborg University Hospital (2) · Al-Azhar University (2) · Children's Hospital Medical Center, Cincinnati (2) · Emory University (2) · First Affiliated Hospital of Wenzhou Medical University (2) · Mahidol University (2) · Medical University of South Carolina (2) · Medical University of Vienna (2)
United States (104) · Canada (19) · China (17) · Egypt (8) · Denmark (5) · Australia (4) · Austria (3) · France (3) · Brazil (2) · Netherlands (2) · Puerto Rico (2) · Russia (2) · Spain (2) · Sweden (2) · Thailand (2)
Andrew D Krystal, MD, MS (2) · Laurie A Zawertailo, PhD (2) · Rudolf Uher, MD, PhD (2) · Abul-fotouh Ahmed (1) · Ahmed A Shokeir, professor of urology (1) · Ahmed Elhaddad, Ass.prof. (1) · Amy Paller, MD (1) · Aysegul Ozerdem, MD, PhD (1) · Basma Gamal Awad Lecturer (1) · Benjamin T Hayes, MD, MS, MPH (1) · Carol Tamminga, M.D. (1) · Carolina Price, MPA (1)
PMID 19151617, PMID 19724732, PMID 20581790, PMID 21623982, PMID 21734685, PMID 22232986, PMID 32966585, PMID 33849856, PMID 34834540, PMID 36413436, PMID 36855177, PMID 36915062, PMID 37005655, PMID 37082807, PMID 37243355, PMID 37399447, PMID 38676734, PMID 39609026, PMID 39711285, PMID 39825419, PMID 40645369, PMID 40866064, PMID 40921646, PMID 41401709, PMID 41462320, PMID 41494146, PMID 41567709, PMID 41640857, PMID 42103384, PMID 42251276, PMID 42264114, PMID 42286600
2023 (4), 2025 (2), 2019 (1), 5UG1DA015831-21 (1), F31AA028751 (1), I01CX001814 (1), I01CX002902 (1), I01RX004823 (1), K23DA055695 (1), K23DA055933 (1), K23DA057387 (1), R01AG051588 (1), R01AG093767 (1), R01DA053342 (1), R01DA057342 (1)